A Phase 2 interventional study of Vipoglanstat and Placebo in Endometriosis, sponsored by Gesynta Pharma AB. Active, not recruiting at 44 sites in 7 countries. Open to female participants aged 18 Years to 44 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Gesynta Pharma AB · Phase 2, Interventional, and Treatment
Among 29 studies in Endometriosis with a site in Poland — 3 open to participants now, 4 under way, none of them phase 3. Endometriosis · Poland.
Among the 29 studies in Endometriosis with a site in Poland, this one is the 13th largest by enrollment of the 27 interventional ones, is one of 2 that started in 2025, is one of 14 in phase 2, and was the 28th registered.
920 studies on the registry are indexed under Endometriosis; 266 are open to participants now.
This study's enrollment of 213 is above the median of 67 across 540 interventional studies indexed under Endometriosis.
Browse Endometriosis studies →3 of the 29 studies in Endometriosis with a site in Poland are open now, in 1 country. Each count lists the studies.
Of the 176 Endometriosis studies recruiting now, 51 (29%) set no upper age limit and 123 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 44 Years · female · no healthy volunteers.
The full table on the hub →29 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2025.
Median enrollment 187 across the 27 interventional studies, 330 across the 2 observational. Of the 22 that completed or were terminated, 11 (50%) have results posted.
20 of 29 have an industry lead sponsor. The 10 most frequent:
Gesynta Pharma AB is the lead sponsor of 4 studies on the registry; none are open to participants now.
Gesynta Pharma AB has 1 study filed under Endometriosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Endometriosis with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07260669Gesynta Pharma ABA Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis | 2027-06 |
Among the 29 studies in Endometriosis with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Endometriosis diagnosis confirmed and documented within the last 10 years prior to Visit 1 or during Visit based on:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Vipoglanstat
Drug: Vipoglanstat
Drug: Placebo
Participants will receive vipoglanstat capsules orally for approximately 4 menstrual cycles during the treatment period.
Participants will receive matching placebo capsules orally for approximately 4 menstrual cycles during the treatment period.
Percentage of Participants who meet the Predefined NMPP Responder Criteria from Baseline to Fourth Month of Treatment
Time frame: Baseline to 4 months
Change in Mean Worst NMPP numeric Rating Scale (NRS) Score from Baseline to Fourth Month of Treatment
Time frame: Baseline to 4 months
Percentage of Participants who Meet the Predefined Dysmenorrhea Responder Criteria from Baseline to Fourth Month of Treatment
Time frame: Baseline to 4 months
Change in Mean Worst Dysmenorrhea NRS Score from Baseline to Fourth Month of Treatment
Time frame: Baseline to 4 months
Change in Endometriosis Health Profile 30 Item Patient Reported Outcome (EHP-30) Score from Baseline to End of Treatment
Time frame: Baseline to 4 months
Change in EHP-30 Sexual Intercourse Subscale Score from Baseline to End of Treatment
Time frame: Baseline to 4 months
Change in Mean Daily Opioid Rescue Medication Use for NMPP from Baseline to Fourth Month of Treatment
Time frame: Baseline to 4 months
Change in Mean Daily Opioid Rescue Medication Use for Dysmenorrhea from Baseline to Fourth Month of Treatment
Time frame: Baseline to 4 months
Number of Participants with Adverse Events
Any clinically significant changes in laboratory variables, including clinical chemistry, hematology, and urinalysis will be reported as adverse events.
Time frame: Up to 10 months
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Jun 2027, 20 months after the start.
Of 44 phase 2 interventional studies under Endometriosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 37. This study's planned 20 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vipoglanstat
Gesynta Pharma AB